Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONNASDAQ:SLSTSE:TEVNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.91+1.1%$1.93$1.60▼$2.54$728.94M1.041.35 million shs773,288 shsSLSSELLAS Life Sciences Group$2.03+9.7%$1.62$0.77▼$2.12$184.59M2.251.61 million shs5.24 million shsTEVTervitaC$0.00C$1.69▼C$6.46C$672.00MN/A79,738 shs15,893 shsTLRYTilray Brands$0.41+4.7%$0.43$0.35▼$2.15$396.36M1.8329.53 million shs19.46 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.06%0.00%-4.50%+6.70%-17.67%SLSSELLAS Life Sciences Group+9.73%+29.30%+5.18%+82.88%+81.25%TEVTervita0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands+4.72%+7.59%-6.97%-37.77%-75.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group2.3851 of 5 stars0.05.00.00.02.50.02.5SLSSELLAS Life Sciences Group0.3408 of 5 stars0.01.00.00.02.11.70.6TEVTervitaN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands2.106 of 5 stars3.12.00.00.03.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 0.00N/AN/AN/ATEVTervita 0.00N/AN/AN/ATLRYTilray Brands 2.25Hold$1.92364.76% UpsideCurrent Analyst Ratings BreakdownLatest TLRY, SLS, CRON, and TEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TLRYTilray BrandsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilray BrandsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.61M6.26$0.00 per share4,061.72$2.90 per share0.66SLSSELLAS Life Sciences Group$1M202.55N/AN/A$0.13 per share15.62TEVTervitaC$1.36B0.00N/A29.62C$1.58 per share0.00TLRYTilray Brands$788.94M0.53N/AN/A$4.14 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.1314.6963.6732.1439.69%-0.07%-0.07%8/6/2025 (Estimated)SLSSELLAS Life Sciences Group-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)TEVTervitaN/A-C$0.01N/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%8/4/2025 (Estimated)Latest TLRY, SLS, CRON, and TEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million4/8/2025Q3 2025TLRYTilray Brands-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATEVTervitaN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A27.8026.75SLSSELLAS Life Sciences GroupN/A4.644.64TEVTervita440.441.000.86TLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%SLSSELLAS Life Sciences Group17.38%TEVTervitaN/ATLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%SLSSELLAS Life Sciences Group1.40%TEVTervitaN/ATLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.68 million357.53 millionOptionableSLSSELLAS Life Sciences Group1099.78 million98.38 millionNot OptionableTEVTervita36,800115.66 millionN/ANot OptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableTLRY, SLS, CRON, and TEV HeadlinesRecent News About These CompaniesTilray Brands (NASDAQ:TLRY) Shares Up 3.9% - Should You Buy?June 26 at 3:06 PM | marketbeat.comTilray Brands (NasdaqGS:TLRY) Advances Medical Cannabis Research With New Bioavailability StudyJune 26 at 2:52 PM | finance.yahoo.comTilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD FormulationsJune 26 at 9:52 AM | finance.yahoo.comMontauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider FoundationJune 26 at 8:00 AM | globenewswire.comTLRY Stock - Tilray Brands Inc Stock Price Quote - XTSE - MorningstarJune 26 at 4:51 AM | morningstar.comMHere Is A List Of 3 Canadian Marijuana Stocks To Watch 2025June 25 at 10:46 AM | marijuanastocks.comMTilray Medical Launches “Good Supply” Cannabis Brand in GermanyJune 25 at 5:48 AM | insidermonkey.comTilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic UseJune 24 at 7:46 PM | finance.yahoo.comTilray sets medical cannabis milestone in ItalyJune 24 at 7:46 PM | msn.comTilray Brands Stock Price, Quotes and Forecasts | NASDAQ:TLRY - BenzingaJune 24 at 7:46 PM | benzinga.comTilray Brands (NASDAQ:TLRY) Trading 4% Higher - Should You Buy?June 24 at 2:17 PM | marketbeat.comTilray Medical Receives Italy's First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic UseJune 24 at 7:00 AM | globenewswire.comTilray Brands, Inc. Unveils Exciting 2025 Summer Cannabis Collection Featuring Innovative Formats and FlavorsJune 23, 2025 | quiverquant.comQElevate Your Summer with Canada’s Leading Cannabis Brands and Products by Tilray BrandsJune 23, 2025 | financialpost.comFElevate Your Summer with Canada's Leading Cannabis Brands and Products by Tilray BrandsJune 23, 2025 | globenewswire.comTilray Brands (NASDAQ:TLRY) Shares Down 3.2% - Should You Sell?June 20, 2025 | marketbeat.comWhy Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market TodayJune 17, 2025 | zacks.comTensions in Middle East Weigh on TSXJune 17, 2025 | theglobeandmail.comTilray (NASDAQ:TLRY) Shares Down 5.8% - What's Next?June 17, 2025 | marketbeat.com3 Canadian Cannabis Stocks Traders Are Watching Closely This WeekJune 17, 2025 | marijuanastocks.comMTilray (NASDAQ:TLRY) Trading 4.5% Higher - Here's WhyJune 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingBy Thomas Hughes | June 26, 2025View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingTLRY, SLS, CRON, and TEV Company DescriptionsCronos Group NASDAQ:CRON$1.91 +0.02 (+1.06%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.91 0.00 (0.00%) As of 06/26/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.SELLAS Life Sciences Group NASDAQ:SLS$2.03 +0.18 (+9.73%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.07 +0.04 (+1.97%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Tervita TSE:TEVTervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada.Tilray Brands NASDAQ:TLRY$0.41 +0.02 (+4.72%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$0.42 +0.01 (+2.81%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
